1. /
  2. About us /
  3. Our people and structure /
  4. Working groups /
  5. Immune Therapies
Screenshot 2025 06 24 At 9.43.30 AM
Mark Hogarth Clarissa Whitehead Bruce Wines
+2

Immune Therapies

We’re creating powerful antibody-based biological drugs to form the basis of next-generation therapeutics.

About

We’re focused on treating human diseases by developing potent new biological drugs. We study how antibodies (a natural product of the immune system) switch the immune system on and off. We also study how we can use this to kill unwanted cancers and infections or prevent destructive inflammation and allergies.

Every antibody is composed of 2 functional parts that provide 2 distinct roles: the Fab and Fc. The Fab is unique in each antibody and specifically detects a target. Importantly, the Fc portion is common to all antibodies. Our focus is on activating the immune system through the antibody’s Fc portion – the part that initiates or controls the effector responses.

Our discoveries of how to transform the immune activation responses in one antibody can transform the action of all. This has broad implications for new treatments across cancer, inflammation and infectious diseases. 

Stellabody® hexamer technology, a simple modification in the Fc-portion, is one of our key discoveries.

It’s a simple but revolutionary and multifaceted technology that has wide-ranging implications for the generation of new biological drugs. Using Stellabody®, we can transform the actions of antibodies to be up to 100 times more effective at cell killing. 

Burnet Logo Trademark Presentation (1)
1/3
IMMUNE THERAPIES GROUP
Meet the team
Stellabody Snippet Image Updated
Igg Website
1/3

Tap an image to expand it in focused view

Resources

Group contacts

Professor Mark Hogarth

Professor Mark Hogarth

Head, Immune Therapies Group
View profile

Group members

Dr Bruce Wines

Dr Bruce Wines

Senior Research Officer, Immune Therapies Group
View profile
Dr Clarissa Whitehead

Dr Clarissa Whitehead

Senior Research Officer
View profile
Professor Mark Hogarth

Professor Mark Hogarth

Head, Immune Therapies Group
View profile
Reema Bajaj

Reema Bajaj

Protein Chemist
View profile
Sandra Esparon

Sandra Esparon

Senior Research Assistant
View profile
On this page